Montai Therapeutics

What Montai Therapeutics does

Montai Therapeutics is a privately held, pre-clinical biopharmaceutical company founded in December 2022 by Flagship Pioneering with a $50 million Series A commitment. Headquartered in Cambridge, Massachusetts, the company is developing oral small-molecule medicines for chronic inflammatory, immunological, and related diseases as alternatives to biologics and infused therapies. Its pipeline is centered on the lead asset MTAI-1025, an oral covalent NRF2 agonist for ulcerative colitis on track for IND-enabling studies and first-in-human trials in 2026, with additional programs in dermatology (transcription-factor and biologic-replacement), rheumatology, respiratory, and an oncology program conducted under a December 2024 strategic collaboration with Pfizer covering NSCLC and obesity.

Montai's core technology is the CONECTA platform, an AI-enabled drug-discovery system that combines multimodal foundation models with proprietary Anthromolecule chemistry. Anthromolecules are bioactive compounds derived from substances humans have chronically consumed; Montai has curated and derivatized over one billion synthetically accessible, drug-like analogs from this chemical space, with scaffolds that differ by more than 99% from traditional drug-development libraries. The CONECTA foundation models are trained on over one billion proprietary data points and integrate target-specific bioactivity predictions with more than 60 physicochemical and drug-like parameters to prioritize covalent binders, allosteric inhibitors, molecular glues, macrocycles, and protein–protein interaction inhibitors. The platform is built on NVIDIA NIM microservices and includes the ComboPath combinatorial-ML model, which was presented at NeurIPS 2023.

Montai is a pre-commercial, partnership-driven business. It generates no product revenue, and its primary external counterparty is Pfizer under Flagship Pioneering's broader strategic partnership, with Ampersand Biomedicines as a collaborating Flagship portfolio company. Senior leadership is drawn from Google, Ancestry, AbbVie, Amgen, Pfizer, and Takeda, and the Scientific Advisory Board includes faculty from MIT, Harvard, the Broad Institute, Trinity College Dublin, and the University of Glasgow. Near-term value creation depends on translating AI-prioritized candidates into clinical proof-of-concept and on securing the next round of financing to fund IND-enabling and Phase 1 activities.

Name

Montai Therapeutics

Legal name

Montai Therapeutics, Inc.

Website

https://montai.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

AI-Enabled Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Small molecule therapeutics
• Machine learning platform
• Chronic disease treatments
• Oral small molecules

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels5 records

Core offering

Montai Therapeutics develops oral small molecule medicines for chronic inflammatory, immunological, and oncological diseases using its proprietary CONECTA AI-enabled drug discovery platform. The platform combines multimodal foundation models trained on over 1 billion proprietary data points with the world's largest curated Anthromolecule chemistry library to identify and prioritize drug candidates across 100+ biological pathways. Its most advanced candidate, MTAI-1025 (an oral NRF2 agonist for ulcerative colitis), is on track for first-in-human trials in 2026, with additional programs in dermatology, rheumatology, and respiratory indications, and an oncology program partnered with Pfizer.

Product overview

Montai Therapeutics operates as a biopharmaceutical company built around its CONECTA Platform — an AI-enabled drug discovery system that leverages proprietary Anthromolecule compounds derived from human-consumed bioactive molecules. The company has curated and derivatized over 1 billion molecules from this untapped chemical space and uses multimodal AI models to identify and optimize drug candidates. The current pipeline includes MTAI-1025 (NRF2 agonist for ulcerative colitis), a transcription factor program for dermatology, a biologic replacement program for dermatology, and a partnership with Pfizer in oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• CONECTA Platform The CONECTA Platform is Montai's AI-enabled drug discovery system that predictably identifies transformative small molecule drugs from vast, previously unexplored Anthromolecule chemical space. It uses advanced multimodal foundation models trained on over one billion proprietary data points across 100+ biological pathways and integrates bioactivity predictions with 60+ physiochemical and drug-like parameters, delivering the equivalent of 1,000+ years of experimental screening in under two days for internal and partnered drug discovery programs.
• MTAI-1025 MTAI-1025 is Montai's lead clinical candidate — an oral NRF2 agonist small molecule developed for ulcerative colitis (gastroenterology). It is a covalent-binding molecule designed as an oral alternative to biologics and infusions for chronic inflammatory disease, with IND-enabling studies and first-in-human trials targeted for 2026.

Quantifiable outcome

• Screening equivalent to 1,000+ years of experimental screening completed in under two days
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• PfizercoreStrategic or Co-development Partner · 6 December 2024Strategic collaboration with Pfizer under Flagship Pioneering's strategic partnership to advance oncology programs targeting non-small cell lung cancer (NSCLC) and obesity using Montai's CONECTA platform and Anthromolecule technology.
• Ampersand BiomedicinesminorStrategic or Co-development PartnerCollaboration with Ampersand Biomedicines and Montai working with Pfizer on obesity and NSCLC treatments under Flagship Pioneering's strategic partnership initiative.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Isomorphic Labs: Alphabet/DeepMind-founded AI drug discovery company applying AlphaFold-derived foundation models to drug design. Comparable in AI-first small molecule discovery with platform ambition.
• Exscientia: AI-driven precision medicine company focused on small molecule drug discovery with multiple clinical-stage programs and a partnership-based model. Comparable in target-based AI drug discovery and business model.
• Insitro: AI/ML-driven drug discovery company combining machine learning with high-throughput biology to discover therapeutics, with platform-based pipeline across multiple therapeutic areas. Closely comparable in core thesis (AI + proprietary data + novel therapeutic discovery).
• Recursion Pharmaceuticals: AI-enabled drug discovery company using high-dimensional biology and foundation models to identify novel therapeutics across multiple indications. Closely comparable platform model with broad pipeline and partnerships with Roche/Bayer.
• Schrödinger: Computational chemistry platform combining physics-based simulation with ML for small molecule discovery, with both internal pipeline and software licensing. Comparable in computational drug discovery with multiple clinical-stage programs.
• Atomwise: AI-driven small molecule drug discovery company using convolutional neural networks for hit identification across multiple therapeutic areas. Comparable in AI-first hit-to-lead discovery and partnership model with pharma.
• BenevolentAI: AI drug discovery company applying knowledge graphs and ML to identify novel therapeutic targets and molecules, with clinical-stage programs. Comparable in AI/ML target identification and small molecule discovery.

Emerging players

• Relay Therapeutics: Precision medicine company using computational approaches and motion-based drug design for small molecule discovery, with clinical-stage oncology programs. Comparable in computational small molecule design though more focused on precision oncology.

Broad incumbents

• Pfizer: Large pharmaceutical company and Montai's strategic partner in oncology (NSCLC, obesity). Relevant as both a customer/partner and a broad incumbent increasingly investing in AI-enabled drug discovery internally.

Others

• Flagship Pioneering: Parent company and founding investor of Montai Therapeutics; large biotech venture creation firm behind Moderna, Tessera, and other platform companies. Relevant as the parent/ecosystem that shapes Montai's strategic direction and follow-on financing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MontaiHealth
• LinkedInlinkedin.com/company/montai-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Montai Therapeutics